In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute ...

Careful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who ...

During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or ...

Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical ...

Stem cell transplant is a promising treatment option for patients with myelodysplastic syndrome (MDS). Still, the decision to ...

Panelists give an overview of chronic graft-vs-host disease, its history of treatment, how it is handled in the modern day, and the study design of AGAVE-201.

The phase 2 BRACELET-1 trial demonstrated that the combination of pelareorep and paclitaxel significantly improved outcomes ...

Panelists discuss what the AGAVE-201 study displayed.

Panelists give an overview of Graft-vs-host Disease and the modern landscape of treatment.